New review finds thyroid cancer drugs linked with longer survival in advanced disease
The analysis found benefits for disease-control time and overall survival, but results varied between studies and medicines.
High evidenceReviewSome caution advised
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Researchers reviewed 18 studies and quantitatively combined results from 13 randomized trials. Compared with placebo, tyrosine kinase inhibitors were associated with a lower risk of disease progression or death during the study periods, and with longer overall survival. The analysis reported the largest progression-free survival benefit for lenvatinib, followed by cabozantinib, but the medicines were not necessarily compared directly with one another in the same trial populations.
Separate comparisons of higher- and lower-dose regimens did not find a statistically significant advantage for higher doses. Updated analyses from the SELECT trial of lenvatinib and the COSMIC-311 trial of cabozantinib were reviewed qualitatively to avoid counting overlapping participants more than once. Those updates were described as showing continued benefits during longer follow-up, but the abstract does not provide all of the underlying results or subgroup details.
The question reviewed
The researchers asked how much tyrosine kinase inhibitors were associated with improved outcomes in advanced thyroid carcinoma. They searched major medical databases and reference lists for randomized controlled trials. Eighteen studies were included in the systematic review, and 14 publications contributed to the meta-analysis; 13 randomized trials involving 2,671 participants were included in the quantitative analyses. The review examined progression-free survival and overall survival in placebo-controlled trials, and also assessed trials comparing different doses. Updated publications from the SELECT lenvatinib trial and the COSMIC-311 cabozantinib trial were synthesized qualitatively to avoid duplicating patient populations.
What the evidence shows
Compared with placebo, tyrosine kinase inhibitors were associated with improved progression-free survival, with a hazard ratio of 0.36 (95% confidence interval, 0.26–0.50). This corresponds to an estimated 64% lower relative risk of disease progression or death during the measured follow-up, although variation between studies was substantial (I² = 83.8%).
The medicines were also associated with improved overall survival, with a hazard ratio of 0.78 (95% confidence interval, 0.67–0.91), corresponding to an estimated 22% lower relative risk of death; no statistical heterogeneity was reported for this outcome (I² = 0%). In the review's cross-trial comparisons, lenvatinib showed the greatest progression-free survival benefit, followed by cabozantinib. Three dose-comparison trials did not show a statistically significant advantage for higher-dose regimens (hazard ratio 1.18; 95% confidence interval, 0.87–1.60).
Who this may apply to
The findings may be relevant to people with advanced thyroid carcinoma who resemble participants in the included randomized trials. They do not necessarily apply to people with earlier-stage thyroid cancer, thyroid cancers not represented in the trials, children, or people with substantially different health conditions or treatment histories. The review compares groups in clinical studies and is not individualized medical advice; it also does not determine which medicine or dose is appropriate for any particular person.
Why it matters
Advanced thyroid carcinoma can be difficult to control, and progression-free and overall survival are clinically important outcomes. This review brings together randomized evidence suggesting that some tyrosine kinase inhibitors can improve these outcomes compared with placebo in the studied advanced-disease populations. It does not establish that one medicine is superior for every patient, because the medicines and trial populations were not all compared directly under the same conditions.
Limitations & evidence assessment
The progression-free survival results varied substantially between studies, which reduces certainty about how consistent the size of benefit is across different medicines and patient groups. Comparisons suggesting that lenvatinib had the greatest benefit were based on results across separate trials and may be affected by differences in participants, disease features, trial design, and follow-up; they should not be treated as direct head-to-head evidence. Updated SELECT and COSMIC-311 findings were synthesized qualitatively rather than combined numerically to avoid duplicate participants. The abstract provides limited information about the individual trials, participant characteristics, follow-up lengths, adverse effects, and how risk of bias affected each result. No statistically significant publication bias was detected, but such tests cannot rule out unpublished or selectively reported evidence.
Why this evidence level: Meta-analysis pooling multiple studies sits at the top of common evidence hierarchies.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
World Journal of Oncology · 2026 · DOI: 10.14740/wjon2842
This review examined human clinical evidence about GLP-1 receptor agonists and neovascular age-related macular degeneration, sometimes called wet age-related macular degeneration, in people with type 2 diabetes. The reviewed studies had conflicting results: one reported higher risk, another lower risk, and two large comparisons found no significant increase. The evidence is observational and does not show that these medicines cause or prevent the eye condition.
A prospective, multicenter phase II trial examined whether removing only the treated tumor area through the anus could preserve the rectum in people with locally advanced rectal cancer who responded well to chemoradiotherapy. Among 80 participants, three-year disease-free survival was 84.8%, and local recurrence occurred in 5.0% during the reported follow-up. Because everyone received local excision and there was no comparison group, the findings do not establish that this approach is as effective as more extensive surgery.
This retrospective human study compared a visual CT scoring method with an automated computer analysis for tracking fibrosing interstitial lung disease. Among 92 people followed with CT scans and lung-function tests, both approaches were associated with changes in lung function and signs of disease progression. The study does not show that either method improves treatment or patient outcomes.
